Table 10.
Geometric Mean PCB levels (ng/g) by LOD < 50%, 50–75%, and ≥75%, NHANES 1999–2004.
| Geometric Mean 2 (ng/g) (95% CI) | ||||
|---|---|---|---|---|
| Analyte 1 | Controls (n) |
Subjects with Combined Risk Factors for PAH (n) |
Control Levels of PCBs | Levels of PCBs in Subjects with Risk Factors for PAH |
| PCB074 | ||||
| <LOD to 50% | 499 | 22 | 5.83 (5.74–5.92) | 6.27 (5.89–6.82) |
| 50−75% | 708 | 92 | 10.48 (10.27–10.69) | 10.93 (10.21–11.69) |
| ≥75% | 658 | 131 | 25.57 (24.65–26.53) | 27.01 (24.96–29.62) a |
| PCB099 | ||||
| <LOD to 50% | 497 | 26 | 4.64 (4.59–4.68) | 4.67 (4.52–5.84) |
| 50−75% | 758 | 73 | 7.07 (6.95–7.19) | 7.48 (7.22–7.75) |
| ≥75% | 703 | 127 | 17.45 (16.57–18.37) | 18.43 (16.85–20.15) |
| PCB118 | ||||
| <LOD to 50% | 340 | 11 | 7.23 (7.11–7.35) | 7.43 (7.10–7.78) |
| 50−75% | 758 | 44 | 12.52 (12.26–12.79) | 13.72 (12.95–14.54) a |
| ≥75% | 700 | 90 | 34.14 (32.62–35.73) | 36.02 (32.43–39.99) a |
| PCB138 | ||||
| <LOD to 50% | 502 | 26 | 18.05 (17.79–18.31) | 18.89 (17.99–19.83) |
| 50−75% | 712 | 82 | 30.28 (29.75–30.82) | 30.99 (29.39–32.68) |
| ≥75% | 686 | 132 | 70.46 (67.69–73.34) | 72.14 (66.12–78.71) a |
| PCB153 | ||||
| <LOD to 50% | 586 | 33 | 25.43 (25.02–25.84) | 27.06 (25.05–29.23) |
| 50–75% | 713 | 88 | 45.42 (44.55–46.30) | 47.09 (45.28–48.98) |
| ≥75% | 700 | 131 | 99.09 (95.46–102.86) | 104.39 (96.94–112.41) a |
| PCB180 | ||||
| <LOD to 50% | 451 | 30 | 19.99 (19.69–20.29) | 20.13 (18.38–22.05) |
| 50–75% | 690 | 90 | 36.37 (35.58–37.19) | 36.73 (34.75–38.82) |
| ≥75% | 681 | 128 | 75.99 (73.65–78.40) | 81.67 (77.15–86.44) a |
1 Lipid adjusted and log-transformed polychlorinated biphenyls (ng/g); 2 Geometric means calculated after applying NHANES sampling weights.; a PCB levels significantly higher in subjects with combined risk factors for PAH compared to control group (p < 0.05).